EE274 Estimated Costs of Adverse Event Management in NSCLC Patients with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Treated with Amivantamab or Mobocertinib after Progression on Platinum-Based Chemotherapy
Jul 1, 2022, 00:00 AM
10.1016/j.jval.2022.04.520
https://www.valueinhealthjournal.com/article/S1098-3015(22)00721-5/fulltext
Section Title :
Section Order :
10461
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00721-5&doi=10.1016/j.jval.2022.04.520